Zollinger–Ellison Syndrome

Zollinger–Ellison Syndrome was first described in 1955 by Drs. Robert Zollinger and Edwin Ellison. They identified the syndrome in patients presenting with severe peptic ulcers, gastric hypersecretion, and non-beta islet cell tumours of the pancreas.

Since its discovery, significant advancements have been made in understanding the disease, particularly the role of gastrinomas in its pathogenesis.

Pathophysiology of ZES

Zollinger–Ellison Syndrome is primarily caused by the presence of gastrinomas, which are tumours that secrete excessive amounts of gastrin. Gastrin is a hormone that stimulates gastric acid production by the parietal cells in the stomach.

In ZES, the overproduction of gastrin leads to hypergastrinemia, resulting in increased gastric acid secretion. This excessive acid can cause multiple, recurrent peptic ulcers, particularly in the duodenum and the jejunum.

Aetiology and causes

The exact cause of gastrinomas in Zollinger–Ellison Syndrome is not fully understood. However, these tumours are often associated with a genetic condition known as Multiple Endocrine Neoplasia type 1 (MEN1). MEN1 is an inherited disorder characterised by the development of tumours in multiple endocrine glands, including the pancreas, parathyroid glands, and pituitary glands. Approximately 25-30% of patients with ZES have MEN1.

Association with gastrin-secreting tumours (gastrinomas)

Gastrinomas are typically small, malignant tumours that can occur in the pancreas, duodenum, or other parts of the digestive tract. They are often slow-growing but can metastasize to the liver, lymph nodes, and other organs. The diagnosis and management of gastrinomas are crucial in controlling the symptoms and complications associated with Zollinger–Ellison Syndrome.

Clinical features and symptoms of Zollinger–Ellison Syndrome

The most common clinical features of Zollinger–Ellison Syndrome are related to the gastrointestinal tract. Patients often present with severe, recurrent peptic ulcers that are resistant to standard ulcer treatments. These ulcers can occur in unusual locations, such as the jejunum.

Common symptoms include:

• Abdominal pain
• Diarrhoea
• Nausea and vomiting
• Gastroesophageal reflux disease (GERD)

Excessive gastric acid production brought on by ZES can lead to significant complications, including:

• Peptic ulcers: Deep, persistent ulcers in the stomach and duodenum.
• Gastrointestinal bleeding: Resulting from ulcer erosion into blood vessels.
• Perforation: Severe ulcers can perforate the stomach or intestinal wall, leading to peritonitis.
• Strictures: Repeated ulceration and healing can cause scarring and narrowing of the digestive tract.

Extra-gastrointestinal symptoms

While gastrointestinal symptoms are most common, Zollinger–Ellison Syndrome can also present with extra-gastrointestinal symptoms due to gastrinoma metastasis or associated conditions. These may include:

• Weight loss
• Fatigue
• Anaemia
• Hormonal imbalances in cases associated with MEN1

Diagnosis of Zollinger–Ellison Syndrome

The diagnosis of ZES involves several steps to confirm hypergastrinemia and identify gastrinomas. Key diagnostic criteria include:

• Elevated fasting serum gastrin levels
• Gastric pH testing to confirm acid hypersecretion

Imaging studies for tumour Localisation

Imaging studies are crucial for locating gastrinomas and assessing their extent. Common imaging modalities include:

• Computed Tomography (CT) Scan: Useful for detecting primary tumours and metastases.
• Magnetic Resonance Imaging (MRI): Provides detailed images of soft tissues.
• Somatostatin Receptor Scintigraphy (SRS): A nuclear medicine test that detects tumours with somatostatin receptors.

Additional tests for gastrinomas

In addition to imaging, other tests can help confirm the presence of gastrinomas, such as:

• Secretin Stimulation Test: Measures the increase in gastrin levels after administration of secretin.
• Endoscopic Ultrasound (EUS): Allows for detailed imaging and biopsy of pancreatic and duodenal lesions.

Treatment options for Zollinger–Ellison Syndrome

Proton Pump Inhibitors (PPIs)

Proton pump inhibitors (PPIs) are the mainstay of medical management for ZES. These medications effectively reduce gastric acid production and help control symptoms and heal peptic ulcers. Commonly used PPIs include omeprazole, lansoprazole, and esomeprazole.

Surgical interventions: tumour resection

Surgical resection of gastrinomas is often considered when feasible. The goals of surgery include:

• Removing the primary tumour to reduce gastrin production.
• Preventing or managing metastatic disease.
• Alleviating symptoms and complications associated with tumour growth.

Surgical options depend on the tumour’s location and extent and may include:

• Enucleation: Removal of small tumours.
• Pancreaticoduodenectomy (Whipple Procedure): For tumours in the pancreatic head.
• Distal pancreatectomy: For tumours in the pancreatic tail or body.

Other therapeutic approaches

Other treatment modalities may be employed in managing ZES, including:

• Somatostatin analogues: Medications like octreotide can help control hormone secretion and tumour growth.
• Chemotherapy: Used for advanced or metastatic gastrinomas.
• Targeted therapy: Investigational treatments targeting specific molecular pathways involved in tumour growth.

Living with Zollinger–Ellison Syndrome

Living with Zollinger–Ellison Syndrome (ZES) involves managing a chronic condition that significantly impacts daily life. Patients must navigate a rigorous treatment regimen that typically includes medications to control excessive gastric acid production, such as proton pump inhibitors, and potentially undergo surgical interventions to remove gastrin-secreting tumours.

Regular medical follow-ups and monitoring are crucial to track disease progression and manage complications, such as peptic ulcers and gastrointestinal bleeding. Lifestyle adjustments, including dietary changes and stress management, play a vital role in minimising symptoms and improving overall well-being.

Support from healthcare providers, patient education, and community resources, such as those offered by Neuroendocrine Cancer Australia (NECA), are essential in helping patients and their families cope with the physical and emotional challenges of living with ZES.

Dietary and lifestyle modifications

Patients with ZES can benefit from dietary and lifestyle changes to manage symptoms and improve overall health. Recommendations include:

• Eating smaller, frequent meals to reduce gastric acid stimulation.
• Avoiding acidic and spicy foods to minimise gastric irritation.
• Limiting caffeine and alcohol intake as they can increase acid production.

Regular monitoring and follow-up care

Ongoing monitoring is essential for managing ZES and preventing complications. Patients should have regular follow-up visits to:

1. Assess the effectiveness of treatment.
2. Monitor for potential side effects of medications.
3. Evaluate for signs of disease progression or recurrence.

Supportive care and resources

Supportive care is crucial for improving the quality of life for patients with ZES. Resources include:

• Patient education: Providing information on disease management and treatment options.
• Support groups: Connecting patients with others facing similar challenges.
• Counselling services: Offering psychological support to cope with the emotional aspects of chronic illness.

Neuroendocrine Cancer Australia (NECA) provides comprehensive support for patients living with Zollinger–Ellison Syndrome (ZES) and their families. NECA offers educational resources to help understand the condition and its management, alongside a dedicated nurse helpline for personalised guidance.

We facilitate connections through support groups, fostering a community of shared experiences and emotional support. NECA also advocates for patient access to the latest treatments and clinical trials, ensuring the best possible care. By providing these resources and support systems, NECA empowers patients and their families to navigate the complexities of living with ZES with confidence and armed with information.

Zollinger–Ellison Syndrome is a complex condition that requires a multidisciplinary approach for effective management. Early diagnosis, appropriate medical and surgical treatments, and ongoing supportive care are essential to improving patient outcomes.

Through continued research and advancements in treatment, the prognosis for individuals with ZES continues to improve. For more information and support, patients are encouraged to contact organisations such as Neuroendocrine Cancer Australia (NECA) for resources and guidance.

Further information and support for people diagnosed with Zollinger–Ellison Syndrome is available by calling the NECA NET nurse line.